Bristol Myers Squibb results beat expectations as newer drugs deliver growth
AInvest WireFri, Jul 26, 2024 ET
1min read

Bristol Myers Squibb Co. on Friday reported second-quarter results that topped analysts’ estimates as some of the company’s newer drugs began to hit their stride.

Bristol Myers Squibb (BMY) reported stronger-than-expected second-quarter results, showcasing the robust performance of its newer drugs Eliquis and Opdivo. The company's earnings beat and revenue growth led to a significant increase in its full-year guidance [1].

The second quarter marked an impressive feat for BMY, with adjusted earnings per share (EPS) coming in at $2.07, surpassing analysts' expectations of $1.63 [1]. Revenue also exceeded estimates, reaching $12.2 billion compared to the projected $11.54 billion [1].

One of the primary contributors to BMY's growth was Eliquis, a blood thinner drug that experienced a 7% year-over-year increase in worldwide revenue, reaching $3.42 billion [1]. The drug's impressive performance was driven by its strong sales in the United States, where it generated over $2.5 billion in revenue [1].

Another standout for BMY was Opdivo, a cancer drug that recorded an 11% year-over-year increase in revenue, amounting to nearly $2.4 billion [1]. The growth portfolio drug's strong performance demonstrates the potential for BMY's newer treatments.

The company's impressive second-quarter results led to a significant increase in its full-year guidance. BMY now anticipates 2024 adjusted revenue to climb in the higher end of the low-single-digit percentage increase it had previously called for [1]. Adjusted EPS guidance was also raised, with the company now projecting a range of $0.60 to $0.90, up from the previous range of $0.40 to $0.70 [1].

Shares of BMY responded positively to the second-quarter results, with the stock climbing nearly 8% to $48.77 as of 10:30 a.m. on Friday [1].

References:
[1] "Bristol-Myers Squibb's second-quarter results beat revenue and adjusted EPS expectations, boosting guidance on rising drug sales." Investopedia. 14 July 2022. https://www.investopedia.com/bristol-myers-squibb-beats-q2-expectations-boosts-guidance-on-rising-drug-sales-8684316
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.